Priya Hays, Hays Documentation Specialists, discusses innovations and advancements in the development of personalized cancer ...

MAIA Biotechnology Announces Positive Efficacy Updates for Phase 2 THIO-101 Trial in Advanced Non-Small Cell Lung Cancer ...

In the ALEXANDRA/IMpassion030 trial, Tecentriq (atezolizumab) added to postoperative chemotherapy was not found to improve treatment outcomes for patients with high-risk early-stage triple-negative ...

Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical-stage biotechnology company pioneering innovative cancer and viral infection treatments, today announced the ...

MAIA Biotechnology (MAIA) announced updated data from its THIO-101 pivotal Phase 2 clinical trial evaluating its lead clinical candidate, THIO, ...

Bristol Myers Squibb (BMY) says its cancer drugs Opdivo and Yervoy improved progression-free survival in a Phase 3 trial for ...

With this acquisition, LipoVation becomes a wholly owned subsidiary of Revium Rx, aligning with the company’s renewed commitment to drug delivery innovation. Revium Rx is developing a portfolio of ...

Discover new treatments currently being developed for pancreatic cancer, which has historically been extremely difficult to ...

Clinicians may one day be able to treat immune checkpoint inhibitor-related myocarditis without disrupting cancer therapy, findings from a cellular investigation showed.Individuals who die of immune ...

HURA READ THE FULL HURA RESEARCH REPORT We are initiating coverage of TuHURA Biosciences, Inc. (NASDAQ:HURA) with a valuation ...

progressing on checkpoint inhibitors (QUILT-3.055): Anticipated BLA submission in 2025 with ongoing randomized Phase 3 trial in NSCLC patients who have failed checkpoint inhibitors (ResQ201A-NSCLC ...

BIO CEO & Investor conference Format: "IPO Class of 2024 Panel" and one-on-one meetings Date: February 10, 2025 Location: New York, NY Registered conference attendees may schedule one-on-one meetings ...